Literature DB >> 10570028

Up-regulation of glutathione S-transferase activity in enterocytes of young children.

J P Gibbs1, C A Liacouras, R N Baldassano, J T Slattery.   

Abstract

The relationship between age and busulfan apparent oral clearance (Cl/F) expressed relative to adjusted ideal body weight and body surface area (bsa) was evaluated in 135 children aged 0 to 16 years undergoing hematopoietic stem cell transplantation for various disorders. Busulfan plasma levels were measured by gas chromatography-mass spectrometry after the first daily dose of the 4-day dosing regimen. Cl/F expressed relative to adjusted ideal body weight (ml/min/kg) and bsa (ml/min/m(2)) was lower in 9- to 16-year-old (y.o.) compared with 0- to 4-y.o. children (49 and 30%; p<.001). We hypothesized that the greater busulfan Cl/F observed in young children was in part due to enhanced (first-pass intestinal) metabolism. Busulfan conjugation rate was compared in incubations with human small intestinal biopsy specimens from healthy young (1- to 3-y.o.) and older (9- to 17-y.o.) children. Villin content in biopsy specimens was determined by Western blot and busulfan conjugation rate was expressed relative to villin content to control for differences in epithelial cell content in pinch biopsies. Intestinal biopsy specimens from young children had a 77% higher busulfan conjugation rate (p =.037) compared with older children. We have previously shown that glutathione-S-transferase (GST) A1-1 is the major isoform involved in busulfan conjugation, and that this enzyme is expressed uniformly along the length of adult small intestine. Thus, the greater busulfan conjugation activity in intestinal biopsies of the young children was most likely due to enhanced GSTA1-1 expression. We conclude that age dependence in busulfan Cl/F appears to result at least in part from enhanced intestinal GSTA1-1 expression in young children.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570028

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  24 in total

1.  Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Authors:  Radojka M Savic; Morton J Cowan; Christopher C Dvorak; Sung-Yun Pai; Luis Pereira; Imke H Bartelink; Jaap J Boelens; Robbert G M Bredius; Rob F Wynn; Geoff D E Cuvelier; Peter J Shaw; Mary A Slatter; Janel Long-Boyle
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-09       Impact factor: 5.742

2.  Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.

Authors:  Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

3.  Neonatal pharmacology: extensive interindividual variability despite limited size.

Authors:  Cuneyt Tayman; Maisa Rayyan; Karel Allegaert
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 4.  Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.

Authors:  J S McCune; P Jacobson; A Wiseman; O Militano
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

5.  Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children : validation of liquid chromatography tandem mass spectrometry method.

Authors:  Manfred Rauh; Daniel Stachel; Michaela Kuhlen; Michael Gröschl; Wolfgang Holter; Wolfgang Rascher
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Authors:  Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar
Journal:  J Clin Pharmacol       Date:  2017-12-14       Impact factor: 3.126

7.  Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.

Authors:  Tiago Nava; Nastya Kassir; Mohamed Aziz Rezgui; Chakradhara Rao Satyanarayana Uppugunduri; Patricia Huezo-Diaz Curtis; Michel Duval; Yves Théoret; Liane E Daudt; Catherine Litalien; Marc Ansari; Maja Krajinovic; Henrique Bittencourt
Journal:  Br J Clin Pharmacol       Date:  2018-04-27       Impact factor: 4.335

8.  Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Authors:  M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

Review 9.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

10.  Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.

Authors:  Jeannine S McCune; K Scott Baker; David K Blough; Alan Gamis; Meagan J Bemer; Megan C Kelton-Rehkopf; Laura Winter; Jeffrey S Barrett
Journal:  J Clin Pharmacol       Date:  2013-01-24       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.